Inspire Veterinary Partners Files 8-K on Material Agreement

TL;DR

Inspire Vet Partners signed a material agreement, filed 8-K.

AI Summary

Inspire Veterinary Partners, Inc. filed an 8-K on September 15, 2025, reporting a material definitive agreement entered into on September 9, 2025. The filing also disclosed unregistered sales of equity securities and included financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Virginia Beach, VA.

Why It Matters

This filing indicates a significant business development for Inspire Veterinary Partners, potentially impacting its operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements and unregistered sales of equity securities can introduce significant business and financial risks.

Key Numbers

• 001-41792 — SEC File Number (Identifier for the company's filings)
• 85-4359258 — EIN (Employer Identification Number)

Key Players & Entities

• INSPIRE VETERINARY PARTNERS, INC. (company) — Registrant
• September 9, 2025 (date) — Date of earliest event reported
• September 15, 2025 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation
• Virginia Beach, VA (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 IVP Nasdaq Capital Market Indicat
• $1.0 million — nts for gross proceeds of approximately $1.0 million. The offering and sale of the shares of

Filing Documents

• ea0257345-8k_inspire.htm (8-K) — 28KB
• ea025734501ex10-1_inspire.htm (EX-10.1) — 35KB
• 0001213900-25-087649.txt ( ) — 234KB
• ivp-20250909.xsd (EX-101.SCH) — 3KB
• ivp-20250909_lab.xml (EX-101.LAB) — 33KB
• ivp-20250909_pre.xml (EX-101.PRE) — 22KB
• ea0257345-8k_inspire_htm.xml (XML) — 4KB

01 Entry into

Item 1.01 Entry into a Material Definitive Agreement. On September 9, 2025, Inspire Veterinary Partners, Inc. (the "Company") entered into an amendment (the "Amendment") to the securities purchase agreement (the "Securities Purchase Agreement") dated July 28, 2025, pursuant to which the Company added certain new institutional investors to the schedule of buyers in the Securities Purchase Agreement, to issue and sell to such new investors, in one or more closings, shares of the Company's Series B convertible preferred stock, par value $0.0001 per share (the "Series B Preferred Stock") and related Warrants (as defined in the Securities Purchase Agreement).

02 Unregistered

Item 3.02 Unregistered Sales of Equity Securities As previously reported on the Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 4, 2025, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell, in one or more closings, up to 10,000 shares of the Company's Series B Preferred Stock, which are convertible into shares of the Company's common stock, par value $0.0001 per share, and related Warrants in a private placement offering. On September 9, 2025, the Company and certain investors effected an Additional Closing (as defined in the Securities Purchase Agreement), with respect to 1,253 additional shares of Series B Preferred Stock and related Warrants for gross proceeds of approximately $1.0 million. The offering and sale of the shares of Series B Preferred Stock and related Warrants were issued and, upon conversion of the Series B Preferred Stock or exercise of the Warrants, as applicable, the shares of Common Stock underlying the Series B Preferred Stock and the Warrants, as applicable, will be issued, in each case, without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. The description of the terms and conditions of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the form of Amendment, which is filed as Exhibit 10.1 hereto. Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Form of Amendment to the Securities Purchase Agreement 104 Cover Page Interactive Data File – the cover page XBRL tags are embedded within

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 15, 2025 INSPIRE VETERINARY PARTNERS, INC. By: /s/ Kimball Carr Name: Kimball Carr Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR